Contrave vs. Qsymia vs. Phentermine Compared | Harbor

Not everyone wants a weekly injection to manage their weight. For millions of Americans navigating obesity treatment, oral medications remain a practical, effective starting point, and in many cases, the preferred long-term choice. Yet despite three well-established oral options sitting on pharmacy shelves, finding a straightforward, side-by-side comparison of Contrave, Qsymia, and phentermine is surprisingly difficult. If you're exploring medically supported weight loss and want to understand your oral options before your next doctor's appointment, or before starting a program through a platform like Harbor, this is the comparison you've been looking for.

How Each Medication Works: Three Different Approaches to Appetite and Weight

Phentermine

Phentermine is the oldest of the three, first approved by the FDA in 1959. It belongs to the sympathomimetic amine class, meaning it stimulates the central nervous system in a way that suppresses appetite. Structurally, it's related to amphetamine, which is why the FDA classifies it as a Schedule IV controlled substance.

Phentermine stimulates the release of norepinephrine in the brain, reducing hunger signals and increasing feelings of satiety. The effect is relatively blunt: you simply feel less hungry. It doesn't target cravings or reward-driven eating in the way the other two medications do. Because of its stimulant properties, the FDA approved phentermine only for short-term use, generally 12 weeks or fewer. However, many obesity medicine specialists prescribe it off-label for longer durations.

Popular weight loss pills spilling from overturned orange bottle wrapped in blue measuring tape on dark background

Contrave: Targeting Cravings and Reward Pathways

Here's how Contrave is believed to work in the body, including its mechanism of action and the brain areas it targets to help control cravings and reduce hunger. Contrave, approved by the FDA in September 2014, takes an entirely different approach. It combines two existing medications — naltrexone (an opioid receptor antagonist used in addiction treatment) and bupropion (an antidepressant and smoking cessation aid) into a single extended-release tablet.

The combination targets the neurological aspects of obesity. Bupropion stimulates pro-opiomelanocortin (POMC) neurons in the hypothalamus, which help regulate appetite. Naltrexone blocks the opioid-mediated feedback loop that would normally dampen that signal. The result is a synergistic effect on both hunger reduction and craving control, particularly the reward-driven eating patterns that make weight management so difficult for many people.

In clinical studies, Contrave has demonstrated meaningful weight-loss effectiveness when combined with diet and exercise. Across multiple randomized, double-blind, placebo-controlled trials, patients taking Contrave achieved an average weight loss of 5% to 8.1% of baseline body weight at 56 weeks, compared with 1.3% to 4.9% in placebo groups. In absolute terms, this translates to an average loss of 12 to 25 pounds with Contrave versus 3 to 16 pounds with placebo, depending on the study and population. Additionally, a greater proportion of Contrave users achieved clinically significant weight loss: between 42% and 57% lost at least 5% of their body weight, compared with 17% to 43% on placebo. Contrave also led to reductions in waist circumference, with average decreases of up to 4.4 inches, exceeding the reductions seen in placebo groups. These results underscore Contrave’s ability to produce sustained weight loss and improvements in central obesity measures beyond what is typically achieved with lifestyle intervention alone.

Contrave is the only FDA-approved, nonstimulant, combination oral weight-loss medication. That distinction matters for patients who can't take stimulants due to cardiovascular concerns, anxiety disorders, or a history of substance use.

Proper Use and Dosing of Contrave

Here's how to properly use Contrave, including dosing information, what to do if a dose is missed, and what to monitor while taking the medication.

Contrave should be taken exactly as prescribed by your healthcare provider to maximize its effectiveness and minimize potential risks. The medication comes as an extended-release tablet that should be swallowed whole with a full glass of water. Do not cut, crush, or chew the tablets. Contrave is typically started at a low dose and gradually increased over several weeks to reach the full maintenance dose, which is often two tablets taken twice daily (totaling 32 mg naltrexone/360 mg bupropion per day). It can be taken with or without food, but it is important to avoid high-fat meals when taking Contrave, as this can increase the risk of seizures. Always try to take the medication at the same time each day to maintain consistent levels in your body.

If you miss a dose of Contrave, simply skip the missed dose and take your next scheduled dose at the usual time. Do not take extra tablets or double up to make up for a missed dose, as this can increase the risk of side effects, particularly seizures. While taking Contrave, regular monitoring is essential. Your healthcare provider will likely check your blood pressure and heart rate before starting treatment and periodically thereafter, since Contrave can raise both.

If you have diabetes, monitoring your blood sugar is important, as weight loss and the medication you take may affect your glucose levels. Additionally, be alert for any changes in mood, behavior, or signs of depression, especially when starting the medication or adjusting the dose, and report any concerning symptoms to your provider promptly. Regular follow-up appointments help ensure that you are responding well to treatment and that any potential side effects are managed appropriately.

Qsymia: The High-Efficacy Combination

Qsymia, approved in July 2012, pairs phentermine with topiramate in an extended-release formulation. Topiramate was originally developed as an anticonvulsant for epilepsy, but clinicians noticed that patients taking it consistently lost weight, a side effect that eventually became its own indication. The combination leverages phentermine's appetite-suppressant effects alongside topiramate's ability to enhance satiety and reduce caloric intake by modulating gamma-aminobutyric acid (GABA). The two mechanisms complement each other, which is why Qsymia produces significantly greater weight loss than either component alone.

Clinical Efficacy: What the Trial Data Actually Shows

Phentermine Alone

Average weight loss with phentermine ranges from 5% to 7% of baseline body weight over six months. At three months, the average is closer to 3%. For a 220-pound individual, that translates to roughly 11 to 15 pounds over half a year. Long-term data are limited because most clinical trials only studied short-term use. However, patients using phentermine continuously for more than 12 months maintained weight loss exceeding 7% of baseline at the two-year mark.

Contrave

The COR (Contrave Obesity Research) clinical trial program, a series of four randomized, placebo-controlled studies, provides the efficacy data for Contrave. Across the program, patients achieved 5% to 6% weight loss at 56 weeks, with 42% to 50% of participants losing at least 5% of their body weight. The COR-BMOD trial, which combined Contrave with intensive behavioral modification, showed the best results: the combination of naltrexone (32 mg) and bupropion (360 mg) produced average weight loss of 5.4%, compared to just 0.8% for placebo. Importantly, that 5.4% was significantly greater than either naltrexone alone (1.2%) or bupropion alone (2.7%), confirming the synergistic benefit of the combination.

Clinical Study Designs: How Contrave Was Evaluated in Clinical Trials

The design of clinical trials evaluating Contrave included the study structure, endpoints measured, and comparisons with placebo.

Contrave’s approval and clinical reputation are grounded in a robust set of randomized, placebo-controlled trials known collectively as the COR (Contrave Obesity Research) program. Understanding the design of these studies is key to interpreting Contrave’s role in weight management and comparing it to other oral medications.

Study Structure and Populations

The pivotal Contrave trials were multicenter, randomized, double-blind, placebo-controlled studies—considered the gold standard for evaluating medical therapies. Participants were adults with obesity (BMI ≥30 kg/m²) or overweight individuals (BMI ≥27 kg/m²) who also had at least one weight-related comorbidity (such as hypertension, dyslipidemia, or type 2 diabetes).

Each study typically spanned 56 weeks, allowing for the assessment of both short- and long-term effects. Participants were randomly assigned to receive either Contrave (naltrexone 32 mg/bupropion 360 mg daily, in extended-release form) or a matching placebo. All participants received lifestyle counseling focused on reduced-calorie diets and increased physical activity.

Some studies, such as COR-BMOD, incorporated intensive behavioral modification. In these, participants attended group sessions led by registered dietitians, behavioral psychologists, or exercise specialists—weekly for the first 16 weeks, biweekly for the next 12 weeks, and monthly thereafter (28 sessions total).

Endpoints Measured

The trials were designed with co-primary and secondary endpoints to comprehensively assess Contrave’s impact:

Co-primary endpoints:

Percent change from baseline body weight at week 56
Proportion of participants achieving ≥5% reduction in body weight at week 56

Secondary endpoints:

Proportion of participants achieving ≥10% weight loss at week 56
Change from baseline waist circumference at week 56
In diabetes-specific studies (e.g., COR-Diabetes), the change in HbA1c at week 56

These endpoints were measured both in the intention-to-treat (ITT) population (all randomized patients with at least one post-baseline measurement) and among study completers.

Placebo Comparison and Behavioral Modification

A key feature of the Contrave clinical program was the use of a placebo group for direct comparison. Both the Contrave and placebo groups received the same intensity of lifestyle counseling, ensuring that any differences in outcomes could be attributed to the medication itself rather than behavioral support alone.

In trials like COR-BMOD, the addition of intensive behavioral modification allowed researchers to evaluate whether Contrave offered benefits beyond those achievable with lifestyle intervention alone. This design helped clarify the unique contribution of the medication to weight loss and metabolic improvements.

Qsymia

Qsymia stands out as the most effective oral weight-loss medication by a meaningful margin. The landmark CONQUER trial enrolled 2,487 patients and found that the maximum dose (15 mg phentermine / 92 mg topiramate) produced average weight loss of 12.4% at 56 weeks, with 70% of participants losing at least 5% and 48% losing at least 10%.

The EQUIP trial reinforced these numbers in a higher-BMI population (BMI >35), showing 14.4% average weight loss at the maximum dose. Even the lower dose (7.5/46 mg) produced a respectable 7% to 8% average weight loss over one year. Two-year data from the SEQUEL extension study showed some weight regain across all groups, but participants on the full dose still maintained an average loss of 10.5%, a durable result that outpaces both Contrave and standalone phentermine by a significant margin.

Side Effects and Safety: What Each Medication Demands of Your Body

Phentermine Side Effects

As a stimulant, phentermine's side effects track predictably: elevated heart rate, increased blood pressure, insomnia, restlessness, dry mouth, and constipation. Some patients experience anxiety, mood changes, or tremor. Because tolerance can develop, the appetite-suppressing effect may diminish after several weeks. Phentermine is contraindicated in patients with cardiovascular disease or a history of drug abuse. It should never be taken within 14 days of a monoamine oxidase inhibitor (MAOI) due to the risk of hypertensive crisis.

Contrave Side Effects

The potential side effects, warnings, and precautions associated with Contrave and interactions with other medications.

Contrave's most common side effects are nausea, constipation, headache, vomiting, dizziness, insomnia, and dry mouth. It can also increase resting heart rate and blood pressure modestly. The most serious safety consideration is Contrave's FDA black box warning, the agency's strongest safety alert, for increased risk of suicidal thoughts and behaviors. This warning stems from bupropion's classification as an antidepressant, and the risk applies particularly during the first few months of treatment or when doses change. Contrave can also lower seizure threshold, making it contraindicated in patients with seizure disorders. It cannot be used alongside opioid medications, MAOIs, or during abrupt discontinuation of alcohol or sedatives.

Contrave is contraindicated for people with uncontrolled hypertension, seizure disorders, or a history of seizures, and those with eating disorders such as anorexia or bulimia, as these conditions significantly increase the risk of seizures. It should also be avoided by individuals currently dependent on opioid medications, those undergoing acute opioid withdrawal, or individuals who have recently discontinued alcohol, benzodiazepines, barbiturates, or antiepileptic drugs abruptly. Additionally, Contrave must not be used by anyone who is taking or has recently taken monoamine oxidase inhibitors (MAOIs) within the past 14 days, due to the risk of serious hypertensive reactions. People with known allergies to naltrexone, bupropion, or any component of Contrave should also avoid this medication.

Certain individuals should not take Contrave due to the risk of serious complications associated with specific medical conditions and medication interactions. Contrave is contraindicated for people with uncontrolled hypertension, seizure disorders, or a history of seizures, and those with eating disorders such as anorexia or bulimia, as these conditions significantly increase the risk of seizures. It should also be avoided by individuals currently dependent on opioid medications, those undergoing acute opioid withdrawal, or individuals who have recently discontinued alcohol, benzodiazepines, barbiturates, or antiepileptic drugs abruptly. Additionally, Contrave must not be used by anyone who is taking or has recently taken monoamine oxidase inhibitors (MAOIs) within the past 14 days, due to the risk of serious hypertensive reactions. People with known allergies to naltrexone, bupropion, or any component of Contrave should also avoid this medication.

Drug interactions are a critical consideration when evaluating Contrave as a weight-loss option. The medication should not be combined with other products containing bupropion (such as Wellbutrin or Zyban) or naltrexone, as this can increase the risk of adverse effects, including seizures. Caution is advised when using Contrave with medications that lower the seizure threshold, such as antipsychotics, tricyclic antidepressants, theophylline, or systemic steroids. Patients taking drugs metabolized by CYP2D6 may require dose adjustments, as Contrave can affect the metabolism of these medications. Opioid analgesics, certain antidepressants, medications for Parkinson’s disease (like amantadine or levodopa), and some blood thinners may also interact with Contrave, potentially leading to reduced effectiveness or increased side effects. It is essential for patients to inform their healthcare provider about all medications, supplements, and substances they use to ensure safe and effective treatment with Contrave.

Patient Experiences with Contrave

Many individuals who have tried Contrave report that it offers a unique approach to weight management, particularly for those who struggle with cravings and emotional eating. Patients often describe their journeys as a turning point in their battle with weight, highlighting how Contrave, when combined with healthy habits like balanced eating and regular exercise, helped them regain control over persistent cravings that had previously undermined their efforts. Some users share that they felt more like themselves again, noting improvements not only in the number on the scale but also in their overall well-being and confidence. Others emphasize that Contrave felt like a worthwhile investment in their health, especially after trying multiple diets or other medications without lasting success. While individual results vary, these testimonials underscore Contrave’s role in supporting real people as they navigate the challenges of weight loss and long-term weight maintenance.

Qsymia Side Effects

The most clinically significant risks involve topiramate. It can cause metabolic acidosis, kidney stones, and carries a teratogenic risk. Topiramate is associated with cleft lip and palate in babies exposed during the first trimester, which is why the FDA requires a negative pregnancy test before starting Qsymia and monthly thereafter for women of reproductive age. Qsymia is only available through a restricted distribution program called the Qsymia REMS.

Cost and Insurance: The Financial Reality

Phentermine

Phentermine is by far the most affordable option. As a decades-old generic, it typically costs under $50 for a 30-day supply without insurance, and prescription discount cards can bring it as low as $10 per month. However, many insurance plans don't cover it because of its short-term indication, and Medicare explicitly excludes weight-loss medications.

Contrave

Contrave is the most expensive of the three. Without insurance, a monthly supply runs approximately $840 at retail. Many insurance plans and Medicare do not cover it. Manufacturer programs like CurAccess can reduce the out-of-pocket cost to $99 or less per month for eligible patients, but that is still well above phentermine and roughly on par with Qsymia's savings programs.

Qsymia

Qsymia's retail price falls in the middle, averaging around $200–$311 for a 30-day supply, depending on the dose. A majority of commercial insurance plans cover Qsymia, though Medicare does not. The manufacturer offers a savings program that brings the cost down to approximately $70 per month ($210 for 90 days) when paying cash, a competitive price point given Qsymia's higher efficacy.

Cost-per-Pound Perspective

When you factor in efficacy, the cost calculus shifts. A patient spending $50 per month on phentermine and losing 5% of body weight isn't necessarily getting a better deal than a patient spending $70 per month on Qsymia and losing 10–12% of body weight. The cost per percentage point of weight loss favors Qsymia, despite its higher sticker price. This is the kind of analysis worth discussing with your prescriber or a weight-management program like Harbor that can help you evaluate the full picture.

Treatment Duration: Short-Term Fix vs. Long-Term Management

Phentermine's Short-Term Label

Phentermine's FDA label limits it to 12 weeks. This makes it fundamentally different from Contrave and Qsymia, which are approved for chronic (long-term) weight management. Many physicians prescribe phentermine for longer periods based on clinical judgment and emerging evidence, but label restrictions affect insurance coverage and refill policies. The short-term framing also creates a practical problem: patients often regain weight after discontinuation because the underlying metabolic and behavioral drivers of obesity haven't changed. Without a transition plan, phentermine alone can become a cycle of loss and regain.

Most effective weight loss pills held in open palm alongside glass of water at home

Contrave and Qsymia as Chronic Therapy

Both Contrave and Qsymia are intended for ongoing use. Obesity is increasingly understood as a chronic, relapsing condition that benefits from sustained pharmacological support. The clinical trials for both drugs ran for at least 56 weeks, and long-term extension data support continued use.

This doesn't mean patients must stay on these medications indefinitely. But the evidence suggests that stopping often leads to partial or complete weight regain, just as stopping blood pressure medication leads to a rise in blood pressure. The decision about duration should be made collaboratively between the patient and provider, taking into account treatment response, side effects, and individual goals.

The rise of GLP-1 receptor agonist injections has reshaped the conversation around obesity treatment. These newer drugs produce weight loss of 15% to 25%, numbers that older oral medications can't match. In December 2025, the FDA even approved an oral form of semaglutide for obesity treatment, further expanding the options. But oral weight-loss medications like Contrave, Qsymia, and phentermine remain clinically relevant for several important reasons. They are accessible. Many patients face GLP-1 shortages, high costs, or insurance denials that make injectables impractical. They are well-studied, with decades of safety data. And for patients who prefer pills over injections, they offer a proven path to meaningful weight loss.

The most effective approach to obesity treatment is often a stepped or combination strategy, where oral medications serve as a first-line option, a bridge to other therapies, or a complement to lifestyle intervention. Programs like Harbor can help patients navigate these choices by matching them with the right treatment based on their medical profile, preferences, and goals, rather than defaulting to whatever's most heavily marketed. What matters most isn't which medication tops a comparison chart. It's whether you have a clear treatment plan, the right clinical support, and a medication regimen that you can sustain. For many patients, that plan starts with one of these three oral options, and understanding the differences between them is the first step toward an informed conversation with your doctor.

Sources: